Landsteiner Genmed has announced that it has obtained 2,055M € of non-dilutive funding from Next Generation EU Funds to study the anticancer effects of new molecules with immunomodulatory properties.
Home - News & events
Landsteiner Genmed Obtains 2,055M € of Non-Dilutive Funding from Next Generation EU Funds to Develop New Anticancer Immunomodulatory Agents
Landsteiner Genmed and Vall d’Hebron Institute of Research Communicate Pioneering Preclinical Efficacy Data on the New Compound NPO-2270 in Heart Failure Models
NPO-2270 ameliorates cardiac dysfunction more effectively than enalapril in two experimental models of heart failure.